Pioneering studies reveal advances in CAR-T therapies targeting solid tumors like glioblastoma and multiple myeloma. Milan’s San Raffaele-Telethon Institute developed engineered CAR-T cells with enhanced cellular communication to fight glioblastoma effectively. Brightpath Biotherapeutics’ BP-2202, an iPS-derived BCMA CAR-NKT therapy, received FDA orphan drug designation for multiple myeloma. Meanwhile, new research highlights improved infiltration of CAR-T cells into solid tumors, promising enhanced efficacy. Additionally, dual immune checkpoint blockade (TIGIT and PD-1) shows encouraging results in liver cancer patients.